potassium bicarbonate + sodium alginate: clinical use

Prescribing considerations

• Confirm the exact formulation, as excipients and sodium content differ.
• Consider sodium and potassium exposure in renal impairment, heart failure, restricted-salt diets or controlled-potassium diets.
• Use caution with hypercalcaemia, nephrocalcinosis or recurrent calcium-containing renal calculi.
• Investigate persistent or atypical symptoms rather than continuing unsupervised symptomatic treatment.

Contraindications and cautions

• Known or suspected hypersensitivity to active ingredients or formulation excipients
• The mint chewable product should not be used in renal failure according to its product warning
• Phenylketonuria requires particular consideration with the aspartame-containing mint chewable formulation

Monitoring

• Routine systemic drug-level monitoring is not applicable because action is physical and local.
• Review renal function, electrolyte restrictions and dietary sodium or potassium requirements when clinically relevant.
• Reassess ongoing symptoms for an alternative diagnosis or reflux complications.

Clinical pharmacology

The active ingredients form a buoyant, near-neutral alginic gel raft that impedes gastro-oesophageal reflux and can entrap bile and pepsin. The effect is local and does not depend on systemic absorption.

Formulation and product differences

• The aniseed product is a viscous oral suspension containing parabens and benzyl alcohol from its flavouring.
• The mint product is a chewable tablet containing aspartame, a source of phenylalanine.
• Both selected formulations contribute sodium, potassium and calcium, but amounts and excipients are product-specific.